NEW YORK, March 20 - Compugen and Millennium Pharmaceuticals on Wednesday said they plan to co-develop software that can help researchers predict protein pathways that could be used in drug discovery and development.
Terms of the open-ended deal, announced on Wednesday, call for Compugen to apply its bioinformatics platform to Millennium's high-throughput technologies, especially its transcriptional profiling tools.
Though financial details of the collaboration were not disclosed, Compugen said that each partner will share the costs as well as the rights "to certain aspects" of the technology they develop.
The products that the partners hope to develop "are more general research tools" that can be used in a variety of disease applications, Mor Amitai, president and CEO of Compugen, said.
No other details were provided by a statement, and Amitai remained mum on specific aspects of the collaboration.